NCT06895928 A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
| NCT ID | NCT06895928 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| Condition | Advanced Solid Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-03-28 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 400 participants in total. It began in 2025-03-28 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. The age of signing the informed consent is 18 -70 years, regardless of gender. 2. At least one measurable lesion according to RECIST v1.1 criteria. 3. The ECOG score is 0 or 1. 4. Expected survival ≥12 weeks. 5. Good level of organ function. 6. Have the ability to give informed consent and to comply with the treatment plan. 7. Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods. Exclusion Criteria: 1. Inadequately treated central nervous system metastases or the presence of uncontrolled or symptomatic active central nervous system metastases. 2. Spinal cord compression not cured by surgery and/or radiotherapy. 3. Subjects with uncontrolled tumor-related pain. 4. Received antitumor therapy within 4 weeks before the start of the study. 5. Subjects with severe cardiovascular and cerebrovascular disease. 6. History of immunodeficiency, including a positive HIV test.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06895928 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Advanced Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06895928 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06895928 currently recruiting?
Yes, NCT06895928 is actively recruiting participants. Contact the research team at yang.wu.yw96@hengrui.com for enrollment information.
Where is the NCT06895928 trial being conducted?
This trial is being conducted at Taiyuan, China.
Who is sponsoring the NCT06895928 clinical trial?
NCT06895928 is sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. The trial plans to enroll 400 participants.